Drug
Garadacimab
Garadacimab: highest development phase Post-Market, developed by CSL. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- CSL
Trials
| Drug | Phase | Indication |
|---|---|---|
| Garadacimab NCT06806657 | Post-Market | Hereditary Angioedema |
Latest
No recent events.
Follow Garadacimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.